Your browser doesn't support javascript.
loading
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.
Lai, Dongbing; Alipanahi, Babak; Fontanillas, Pierre; Schwantes-An, Tae-Hwi; Aasly, Jan; Alcalay, Roy N; Beecham, Gary W; Berg, Daniela; Bressman, Susan; Brice, Alexis; Brockman, Kathrin; Clark, Lorraine; Cookson, Mark; Das, Sayantan; Van Deerlin, Vivianna; Follett, Jordan; Farrer, Matthew J; Trinh, Joanne; Gasser, Thomas; Goldwurm, Stefano; Gustavsson, Emil; Klein, Christine; Lang, Anthony E; Langston, J William; Latourelle, Jeanne; Lynch, Timothy; Marder, Karen; Marras, Connie; Martin, Eden R; McLean, Cory Y; Mejia-Santana, Helen; Molho, Eric; Myers, Richard H; Nuytemans, Karen; Ozelius, Laurie; Payami, Haydeh; Raymond, Deborah; Rogaeva, Ekaterina; Rogers, Michael P; Ross, Owen A; Samii, Ali; Saunders-Pullman, Rachel; Schüle, Birgitt; Schulte, Claudia; Scott, William K; Tanner, Caroline; Tolosa, Eduardo; Tomkins, James E; Vilas, Dolores; Trojanowski, John Q.
Afiliación
  • Lai D; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN.
  • Alipanahi B; 23andMe, Inc., Sunnyvale, CA.
  • Fontanillas P; Google LLC, Palo Alto, CA.
  • Schwantes-An TH; 23andMe, Inc., Sunnyvale, CA.
  • Aasly J; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN.
  • Alcalay RN; Department of Neurology, St. Olavs Hospital, Trondheim, Norway.
  • Beecham GW; Department of Neurology, Columbia University, New York, NY.
  • Berg D; John P. Hussman Institute for Human Genomics and Dr. John T. Macdonald Department of Human Genetics, University of Miami, Miller School of Medicine, Miami, FL.
  • Bressman S; Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany.
  • Brice A; Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
  • Brockman K; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Clark L; Sorbonne Université, Institut du Cerveau et de la Moelle épinière (ICM), AP-HP, Inserm, CNRS, University Hospital Pitié-Salpêtrière, Paris, France.
  • Cookson M; Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
  • Das S; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
  • Van Deerlin V; Department of Pathology and Cell Biology, Columbia University, New York, NY.
  • Follett J; Laboratory of Neurogenetics, National Institute of Aging, National Institute of Health, Bethesda, MD.
  • Farrer MJ; 23andMe, Inc., Sunnyvale, CA.
  • Trinh J; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
  • Gasser T; Laboratory of Neurogenetics and Neuroscience, Fixel Institute for Neurological Diseases, McKnight Brain Institute, L5-101D, UF Clinical and Translational Science Institute, University of Florida, Gainesville, FL.
  • Goldwurm S; Laboratory of Neurogenetics and Neuroscience, Fixel Institute for Neurological Diseases, McKnight Brain Institute, L5-101D, UF Clinical and Translational Science Institute, University of Florida, Gainesville, FL.
  • Gustavsson E; Institute of Neurogenetics, University of Luebeck, Luebeck, Germany.
  • Klein C; Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
  • Lang AE; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
  • Langston JW; Parkinson Institute, ASST "G.Pini-CTO, Milan, Italy.
  • Latourelle J; Centre for Applied Neurogenetics, University of British Columbia, Vancouver, Canada.
  • Lynch T; Institute of Neurogenetics, University of Luebeck, Luebeck, Germany.
  • Marder K; The Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Canada.
  • Marras C; Departments of Neurology, Neuroscience, and Pathology, Stanford University School of Medicine, Stanford, CA.
  • Martin ER; GNS Healthcare, Cambridge, MA.
  • McLean CY; Dublin Neurological Institute at the Mater Misericordiae University Hospital, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
  • Mejia-Santana H; Department of Neurology and Psychiatry, Taub Institute and Sergievsky Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY.
  • Molho E; The Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Canada.
  • Myers RH; John P. Hussman Institute for Human Genomics and Dr. John T. Macdonald Department of Human Genetics, University of Miami, Miller School of Medicine, Miami, FL.
  • Nuytemans K; 23andMe, Inc., Sunnyvale, CA.
  • Ozelius L; Google LLC, Cambridge, MA.
  • Payami H; Gertrude H. Sergievsky Center, Columbia University, New York, NY.
  • Raymond D; Department of Neurology, Albany Medical College, Albany, NY.
  • Rogaeva E; Department of Neurology, Boston University, Boston, MA.
  • Rogers MP; John P. Hussman Institute for Human Genomics and Dr. John T. Macdonald Department of Human Genetics, University of Miami, Miller School of Medicine, Miami, FL.
  • Ross OA; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Samii A; Department of Neurology, University of Alabama at Birmingham, Birmingham, AL.
  • Saunders-Pullman R; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Schüle B; Tanz Centre for Research in Neurodegenerative Diseases and Department of Neurology, University of Toronto, Toronto, Canada.
  • Schulte C; Department of General Surgery, University of South Florida Morsani College of Medicine, Tampa, FL.
  • Scott WK; Departments of Neuroscience and Clinical Genomics, Mayo Clinic, Jacksonville, FL.
  • Tanner C; School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.
  • Tolosa E; VA Puget Sound Health Care System and Department of Neurology, University of Washington, Seattle, WA.
  • Tomkins JE; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Vilas D; Department of Pathology, Stanford University School of Medicine, Stanford, CA.
  • Trojanowski JQ; Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Ann Neurol ; 90(1): 76-88, 2021 07.
Article en En | MEDLINE | ID: mdl-33938021
ABSTRACT

OBJECTIVE:

The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age-at-onset of Parkinson's disease.

METHODS:

We performed the first genomewide association study of penetrance and age-at-onset of Parkinson's disease in LRRK2 mutation carriers (776 cases and 1,103 non-cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age-at-onset of LRRK2 mutations, respectively. We also investigated whether a polygenic risk score derived from a published genomewide association study of Parkinson's disease was able to explain variability in penetrance and age-at-onset in LRRK2 mutation carriers.

RESULTS:

A variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; p value = 2.5E-08, beta = 1.27, SE = 0.23, risk allele C) met genomewide significance for the penetrance model. Co-immunoprecipitation analyses of LRRK2 and CORO1C supported an interaction between these 2 proteins. A region on chromosome 3, within a previously reported linkage peak for Parkinson's disease susceptibility, showed suggestive associations in both models (penetrance top variant p value = 1.1E-07; age-at-onset top variant p value = 9.3E-07). A polygenic risk score derived from publicly available Parkinson's disease summary statistics was a significant predictor of penetrance, but not of age-at-onset.

INTERPRETATION:

This study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 mutations. In addition, common Parkinson's disease associated variants collectively increase the penetrance of LRRK2 mutations. ANN NEUROL 2021;9082-94.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Proteína 2 Quinasa Serina-Treonina Rica en Repeticiones de Leucina Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Neurol Año: 2021 Tipo del documento: Article País de afiliación: India

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Proteína 2 Quinasa Serina-Treonina Rica en Repeticiones de Leucina Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Neurol Año: 2021 Tipo del documento: Article País de afiliación: India